Allogeneic Stem Cell Clinical Trials

1 recruitingLast updated: May 5, 2026

There are 10 actively recruiting allogeneic stem cell clinical trials across 4 countries. Studies span Phase 2, Phase 1. Top locations include Cincinnati, Ohio, United States, Boston, Massachusetts, United States, Aurora, Colorado, United States. Updated daily from ClinicalTrials.gov.


Allogeneic Stem Cell Trials at a Glance

10 actively recruiting trials for allogeneic stem cell are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Cincinnati, Boston, and Aurora. Lead sponsors running allogeneic stem cell studies include Children's Hospital Medical Center, Cincinnati, Hackensack Meridian Health, and Center for International Blood and Marrow Transplant Research.

Browse allogeneic stem cell trials by phase

Treatments under study

About Allogeneic Stem Cell Clinical Trials

Looking for clinical trials for Allogeneic Stem Cell? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Allogeneic Stem Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Allogeneic Stem Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

allogeneic stem cell transplantation
Children's Hospital Medical Center, Cincinnati419 enrolled3 locationsNCT05579639
Recruiting
Phase 2

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

Graft-Versus-Host-Disease (GVHD)allogeneic stem cell transplantationHematologic Malignancies
Milton S. Hershey Medical Center41 enrolled1 locationNCT06926595
Recruiting
Phase 2

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Allogeneic Stem Cell Transplant Recipient
Hackensack Meridian Health209 enrolled3 locationsNCT07214688
Recruiting
Phase 2

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

allogeneic stem cell transplantationHematologic MalignanciesALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
University of California, Irvine60 enrolled1 locationNCT06028828
Recruiting
Phase 1Phase 2

Donor-Derived Viral Specific T-cells (VSTs)

Viral reactivationallogeneic stem cell transplantViral Infection
Children's Hospital Medical Center, Cincinnati750 enrolled3 locationsNCT02048332
Recruiting

CIBMTR Research Database

allogeneic stem cell transplantationSolid TumorsBlood Cancers+4 more
Center for International Blood and Marrow Transplant Research99,999,999 enrolled2 locationsNCT01166009
Recruiting
Phase 2

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Myelodysplastic SyndromeDiffuse Large B-Cell Lymphoma (DLBCL)Acute Myeloid Leukaemia+2 more
Vastra Gotaland Region100 enrolled5 locationsNCT06793410
Recruiting
Phase 2

Feasibility of prebiotic fibre supplementation during allogeneic stem cell transplantation

allogeneic stem cell transplantation
Metro North Hospital and Health Service36 enrolled1 locationACTRN12624000262505
Recruiting

The host-microbiome in specialty patient populations

Immunecompromisedallogeneic stem cell transplantLeukemia
Royal Melbourne Hospital768 enrolled3 locationsACTRN12623001105639
Recruiting
Phase 2

Phase I/II clinical trial to assess the safety and biological efficacy of treatment with virus-specific, cytotoxic T-lymphocytes from partially matched third-party unrelated donors, in stem cell transplant patients with viral reactivation unresponsive to standard therapy (R3ACT trial)

Viral reactivation post-allogeneic stem cell transplant
Western Sydney Local Health Districit30 enrolled15 locationsACTRN12613000603718